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Introduction Carotid angioplasty and stenting 
Stroke is one of the leading causes of death in the 
Western world. 1 The personal cost, and burden upon 
the community, is high, with 30% of survivors having 
a major residual handicap. In the 1950s carotid en- 
darterectomy was introduced as surgical prophylaxis 
against stroke due to ipsilateral carotid disease. The 
technique followed the typical marital story of all new 
developments; anecstatic honeymoon phase, followed 
by serious introspection and eventual realistic har- 
monisation. The clarification of the role of carotid 
endarterectomy in limiting stroke was provided by 
two large randomised trials. Both the MRC European 
Carotid Surgery Trial, ~ and the North American Symp- 
tomatic Carotid Endarterectomy TriaP clearly dem- 
onstrated improvement in outcome for patients with 
symptomatic tight (>70%) ipsilateral carotid stenoses 
over and above best medical therapy. Carotid end- 
arterectomy, however, is not the perfect prophylaxis. 
Thirty-day outcome following surgery in the MRC 
study was associated with a death and major stroke 
rate of 3.7% and death and all stroke rate of 7.5%. 
Similarly the NASCET study had corresponding rates 
of 2.1 and 5.8%. The NASCET study also highlighted 
a 7.6% rate of cranial nerve injury, wound com- 
plications in 8.9%, myocardial infarction in 0.9%, con- 
gestive heart failure in 0.6%, and other cardiovascular 
problems in 1.2% of patients. For many patients erious 
cranial nerve injury is as incapacitating as stroke. 
Despite these reservations the data clearly provides 
level 1 evidence 4 to support the use of carotid end- 
arterectomy as prophylaxis against stroke in a selected 
group of patients. 
The combination of evolving clinical practice, and 
a close collaboration with commercial expertise in 
providing outstanding miniaturisation and safety of 
endovascular devices, has resulted in the use of balloon 
dilatation and stent placement in most arterial systems 
throughout the body. It is not surprising that the use 
of these techniques to manage symptomatic carotid 
artery stenosis has evolved, but because of the critical 
nature of the end organ involved development was 
initially tempered. Kerber 5 reported the intraoperative 
dilatation of carotid disease in 1980, and in 1983 
Bockenheimer and Mathias 6reported four patients and 
Wiggli and Gratzl 7 two patients using percutaneous 
techniques. Enthusiasm was initially slow to develop, 
but there has recently been a profusion of proffered 
papers and scientific meetings focused upon the use 
of endovascular techniques in carotid arteries. 
Access for the delivery of endovascular therapy is 
usually via the femoral artery, although Bergeron 8 has 
recently published his own series of direct access via 
a common carotid artery puncture without significant 
local complications. The question arises as to whether 
to treat the offending lesion by simple balloon an- 
gioplasty or by stent placement. There is, however, a 
basic difference in the rationale behind the use of these 
techniques to treat carotid and non-carotid athero- 
sclerosis. Whereas endovascular techniques away from 
the carotid territory are used to treat lesions causing 
ischaemia due to reduced flow, the sequelae of carotid 
disease are usually due to embolisation. There are data 
from other vascular territories to support the use of 
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endovascular techniques in embolic disease; blue digit 
syndromes have been well managed by balloon an- 
gioplasty. 9 Angioplasty is dependent upon the ability 
of the balloon to disrupt the vessel wall, eventually 
resulting in a smooth neo-intima that will not produce 
distal embolisation. Since we are not treating flow- 
limiting disease, then in the short-term it may not be 
necessary to produce avessel with a residual diameter 
of greater than 50%. Clearly the procedure must be 
undertaken with every effort made to minimise distal 
embolisation. Proponents of stent placement suggest 
that these metallic devices may indeed limit distal 
embolisation by either pinning back the disrupted 
atheroma, or producing a less disrupted surface and 
therefore limiting subsequent thrombus formation and 
embolisation. I think that the mode of deployment of 
the Wallstent and its subsequent remodelling during 
optimisation means there will be distal embolisation, 
and the Palmaz stent must be potentially more ag- 
gressive than the smooth contours of a balloon. The 
balloon-expandable Palmaz stent is associated with 
deformity in 10% of cases ~° and this has led to the more 
widespread use of the Wallstent. This self-expanding 
stent has the potential advantages of not being per- 
manently deformed following external compression 
and being able to cover both internal carotid and 
common carotid artery. Undoubtedly the residual 
lumen following stent placement is better than that 
following balloon dilatation and the benefits of this 
may be that there is less restenosis in the long-term 
(see later). Despite these clear shortcomings it is likely 
that in the future any major randomised work under- 
taken will follow the unstoppable American movement 
towards routine primary stenting of the carotid dis- 
ease. There is now widespread commercial interest 
and finance directed at developing the ideal carotid 
stent. Such a stent must either be self-expanding so as 
to recoil following crush injury, or have sufficient hoop 
strength to resist compression. It must be able to cover 
ostial disease and coexistent common carotid disease, 
otherwise itwill only be of value in approximately 30% 
of lesions (personal data). Delivery systems hould be 
low profile and the stent must be radio-opaque and 
non-thrombogenic. Whilst a covered stent would be 
ideal to limit distal embolisation, contemporary de- 
signs are too bulky and they would of course occlude 
the external carotid artery. In the future the potential 
exists for local radiotherapy and drug delivery. 
The limitation of distal embolisation during intra- 
vascular manipulation is foremost in most prac- 
titioners' minds. The use of a distal protection as 
developed by Theron is well known. Essentially a 
small distal occlusion balloon is placed in the internal 
carotid artery prior to intervention and debris is then 
either aspirated from the internal carotid artery or 
flushed from the internal carotid artery into the ex- 
ternal carotid artery prior to deflation of the protection 
balloons. KacheP 1 has employed an alternative ap- 
proach using a guiding catheter with an integral oc- 
clusion balloon at its tip. Prior to intervention the 
balloon is inflated in the common carotid artery, thus 
encouraging retrograde flow down the internal carotid 
artery. Debris is either relocated into the external ca- 
rotid artery by the retrograde flow or it is aspirated 
through the guiding catheter following intervention. 
Once again there is great movement in the commercial 
world to develop user-friendly cerebral protection sys- 
tems. 
Available data 
The endovascular management of symptomatic a- 
rotid disease is a new concept and necessarily the 
published data are much less than that available for 
carotid endarterectomy. Unfortunately much of the 
available information is not of the highest quality. 
Not only are asymptomatic and symptomatic patients 
reported together, but also non-atheromatous di ease 
is combined with atherosclerotic stenosis, and outcome 
data are often poorly documented. 
Kachel 1~ reviewed the available data to 1996 and 
commented that in more than 500 patients reported 
in the literature there was a 0% mortality and a 2.1% 
morbidity. Given the morbidity associated with simple 
selective carotid angiography (0.5-3.2% complication 
rate 12) these data are difficult to interpret with any 
degree of confidence. It is certainly contrary to our 
own experience of 108 patients with symptomatic 
atherosclerotic internal carotid stenoses of greater than 
70%. Using a mixture of balloon dilatation and stent 
placement we have recorded a 4.6% death and dis- 
abling stroke rate, or a 5.6% death and all stroke rate. 
Towards the end of 1996 and through 1997 there 
have been a number of sizeable series published. Gil- 
Peralta 13 and colleagues treated 87 patients with high 
grade (>70%) symptomatic nternal carotid artery dis- 
ease with simple balloon dilatation. They report a 4.9% 
death and disabling stroke rate with 3.7% of patients 
suffering a TIA. They failed to cross the lesion in 5% 
of patients. At 4 years over 95% of their patients were 
free of ipsilateral disabling strokes. The Alabama 1° 
group has published a group of 107 patients with 126 
carotid arteries treated by primary stenting, using a 
variety of devices, and without cerebral protection. 
All treatments were completed successfully, reducing 
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the stenosis from a mean of 78% (range 53-100%) 
to 2% (range 10-25%). The procedural complications 
reported include 4.7% minor stroke, 0.8% major stroke 
and no deaths. At 30 days there was a further major 
stroke in one patient, minor stroke in one patient and 
one death. Overall they report a 30 day major stroke 
and death rate of 2.4% when 126 carotid arteries 
were treated. Sixty-four per cent of their patients were 
symptomatic and all but two minor strokes occurred 
in this group. At short-term follow-up there were no 
late strokes. Eckert 14 and colleagues treated 58 patients 
with symptomatic nternal carotid artery stenoses of 
>70% narrowing according to the NASCET criteria. 
They had an 81% success rate, with no deaths and 
only one major stroke (2%). At a mean of 16 months 
follow-up there was one stroke death, and a further 
stroke following restenosis. Therons 'is group pub- 
lished a large series of 259 patients, 26% of whom were 
asymptomatic. The disease was distributed throughout 
the common carotid artery, internal carotid artery and 
siphon and included non-atheromatous di ease. In the 
patients with atherosclerosis treated without cerebral 
protection using simple balloon dilatation (38 patients) 
there was one death and one major CVA. In 43 patients 
treated with cerebral protection and without a stent 
there were no complications. In 93 patients treated 
with cerebral protection and a stent there were no 
deaths but two cerebral emboli were successfully 
treated with Urokinase with "an excellent result". This 
paper would support the use of cerebral protection 
and it also suggested a reduced restenosis rate in the 
stent group. Whilst the definition of restenosis i  not 
provided, they state that patients with inflammatory 
disease had a 4% restenosis rate, those with no stent 
a 16% restenosis rate, whilst the use of a stent conferred 
long-term benefit in the form of 4% restenosis. 
Clearly there is marked variability in the reported 
complications of treating internal carotid artery sten- 
osis using endovascular techniques which presumably 
suffers from the same problems of self audit as that 
eloquently described by RothwellJ 6 The quality of 
long-term data suffers from poor reporting and low 
numbers. 
Comparison against surgery 
The peri-procedural complication rates detailed above 
provide interesting food for thought and, in the ab- 
sence of a randomised trial, needs to be compared 
against the published results of carotid en- 
darterectomy. However, even here, the problem of 
defining acceptable practice remains difficult. The pub- 
lished results from the MRC study and NASCET are 
excellent, but necessarily involve a selected group of 
patients and selected practitioners. Away from these 
well structured studies a risk of stroke and/or death 
following endarterectomy has been reviewed at 5.64% 
(95% confidence intervals 4.4-6.9). 17 Our own results 
and the published ata are comparable with this sur- 
gical 30-day complication rate. In 1995 The American 
Heart Association issued guidelines pertaining to the 
practice of carotid endarterectomy. 18 In their special 
report hey indicated that in the setting of symptomatic 
disease surgeons hould have a morbidity and mor- 
tality rate of less than 6%. Again, the data presented 
here would suggest that some endovascular prac- 
titioners have acceptable 30-day complication rates. 
The carotid and vertebral artery transluminal an- 
gioplasty randomised trial (CAVATAS) is near com- 
pletion and was designed using the same uncertainty 
principle utilised in the MRC carotid surgery trial. 
Patients with symptomatic carotid disease and sten- 
oses >50% were randomly allocated to either carotid 
endarterectomy or endovascular t eatment if patients 
were fit for surgery, or endovascular t eatment versus 
best medical therapy if patients were not suitable for 
surgery. Thirteen centres from around the world have 
recruited over 500 patients to the trial, which is due 
for publication early 1998. Prior to this the preliminary 
reports from the Data Monitoring Committee have 
indicated that there is no reason to stop the trial 
implying similar immediate complication rates of both 
surgery and endovascular intervention. The complete 
results are eagerly awaited. In the meantime it is clear 
that the endovascular management of carotid disease 
is not associated with the same non-embolic om- 
plications (cranial nerve palsy, etc.) as carotid end- 
arterectomy. Patients are in hospital for 2-4 days, 
whereas the mean inpatient hospital stay following 
carotid endarterectomy, as reported by the Vascular 
Surgical Society audit, is 7.1 days. 19 With more ag- 
gressive short-term surgical management the pro- 
cedural cost benefits of endovascular t eatment may 
disappear, particularly given the high costs of stents. 
Conclusion 
We are witnessing the early development of a po- 
tentially useful technique that is still passing through 
its happy honeymoon phase. Undoubtedly some dis- 
harmony is around the corner and much work needs 
to be done. The potential benefits of non-surgical 
management of carotid disease under local anaesthesia 
with short hospital stay and no cranial nerve injury 
are alluring. It would be foolish to ignore a technique 
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that may have benefit over surgery for some patients; 
the challenge is to define that group. Potential in- 
dications at present are those lesions that are tech- 
nically difficult or high risk for conventional 
endarterectomy (e.g. restenosis, high lesions, post 
radiotherapy) or in patients truly unfit for surgery. In 
addition we have found it useful to combine en- 
dovascular and conventional techniques by stenting 
common carotid origin lesions at the same time as 
endarterectomy of an internal carotid stenosis. Perhaps 
attention could also be directed at the staged en- 
dovascular management of asymptomatic high grade 
stenoses in patients who also require coronary artery 
bypass surgery. Considerable refinement of the tech- 
nique with well designed stents and cerebral protection 
systems till requires considerable financial investment 
and good science. Until such dedicated systems are 
available a large randomised trial is probably pre- 
mature. However, given the considerable controversy 
surrounding this whole subject, 2°-23 it is not surprising 
that at least two large studies have been proposed 
centred on the U.S.A. Until such time as large scale 
data is available, the use of endovascular techniques 
to manage symptomatic atherosclerotic carotid disease 
should be limited to well structured research. 
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